Loading stock data…
IXHL
$4.55+0.16 (+3.64%)
After Hours$4.55-0.00 (-0.01%)· Last close May 1
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incannex Healthcare Inc. in the Healthcare sector is trading at $4.55. The stock is currently near its 52-week low of $2.40, remaining 59.0% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why IXHL maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.55
Potential Upside
5%
Whystock Fair Value$4.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose com...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$57.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.73
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.62%
Volume
Today's trading volume
355,199
Recent News
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 11 Best Pot Stocks to Buy According to Hedge Funds. On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held […]
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Rebranded Italian Medical Cannabis Arm as Tilray Medical Italia Aurora Cannabis Won EU-wide Protection for its Farm Gas and Sourdough Cannabis Varieties Simply Solventless Sharpened Growth Strategy with Uncommon Cannabis Acquisition and Humble Retrofit Progress Key Takeaways; Psychedelic Sector Definium Therapeutics Launched ‘Rerouting Minds’ Campaign to Spotlight the Science Behind […]
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1% and the Hea
Wall Street Set to Open Higher Friday as Investors Await Powell's Speech at Jackson Hole
US stocks are set to open higher in Friday's trading session as investors look ahead to Federal Rese